Summary
EudraCT Number: 2006-002276-17
Sponsor's Protocol Code Number: ET-B-025-02
National Competent Authority: Spain - AEMPS 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2006-06-26
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2006-002276-17/ES/

A. Protocol Information
A.1 Member State Concerned: Spain - AEMPS
A.2 EudraCT number: 2006-002276-17
A.3 Full title of the trial: Phase II Study of Yondelis® in Men with Advanced Prostate Carcinoma

Estudio fase II con Yondelis en hombres con cáncer de próstata avanzado
A.4.1 Sponsor's protocol code number: ET-B-025-02
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Pharma Mar SA, Sociedad Unipersonal
B.1.3.4	Country: Spain
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: YONDELIS (trabectedin)
D.3.2 Product code: ET-743, R279741, RWJ-680581
D.3.4 Pharmaceutical form: Powder for solution for infusion
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: trabectedin
D.3.9.1 CAS number: 114899-77-3
D.3.9.2 Current sponsor code: ET-743
D.3.9.3 Other descriptive name: Ecteinascidin 743
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 1.0 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Information not present in EudraCT
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: YONDELIS (trabectedin)
D.3.2 Product code: ET-743, R279741; RWJ680581
D.3.4 Pharmaceutical form: Powder for solution for infusion
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: trabectedin
D.3.9.1 CAS number: 114899-77-3
D.3.9.2 Current sponsor code: ET-743
D.3.9.3 Other descriptive name: Ecteinascidin 743
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 1.0 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: Information not present in EudraCT
D.3.11.8 Extractive medicinal product: Information not present in EudraCT
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Advanced Prostate Carcinoma

MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 7.1
E.1.2 Level: PT
E.1.2 Classification code: 10036909
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: To determine the safety and efficacy of Yondelis®(trabectedin) treatment in metastatic prostate carcinoma

In Cohort A: To measure PSA response in men with AIPC treated with Yondelis®

In Cohort B: To measure PSA response, duration of response, and time to progression in an additional cohort of 16 prostate cancer  subjects previously treated with docetaxel  that will be treated with YONDELIS®  administered by a 24-h infusion every 3 weeks

E.2.2 Secondary objectives of the trial: In Cohort A:
To assess the safety of administration of Yondelis® as a weekly, three-hour
infusion in this population of patients.
To measure , duration of response and time to progression in men with AIPC treated
with Yondelis®.
In Cohort B: 
To assess the safety of administration of Yondelis® as a 24-hours infusion every three weeks in  these subjects

E.2.3 Trial contains a sub-study: Information not present in EudraCT
E.3 Principal inclusion criteria: In Cohort A:
. Signed informed consent
· Histologically confirmed adenocarcinoma of the prostate
· Radiographically documented metastatic disease
· Surgical or chemical castration
· PSA > 5 ng/ml
· Androgen-independent disease, as defined by detectable, rising PSA in two consecutive measurements at least one week apart, with a minimum increment of at least 5 ng/ml above the nadir
· No more than one previous chemotherapy regimen
· ECOG/WHO performance status of 0, 1 or 2
· Adequate bone marrow reserve(s):
- Neutrophil count > 1,500/ ml
- Platelet count > 100,000/ ml
· Adequate hepatic function:
- Serum bilirubin < 1.0 x upper limit of normal
- Serum alkaline phosphatase < 1.5 x upper limit of normal
NOTE: If serum alkaline phosphatase is elevated, measurement of 5’ nucleotidase (5’NT) and gamma glutamyl transferasa (GGT) or alkaline phosphatase liver fraction should be performed, and if either of these is within normal limits (suggesting bone origin of abnormal alkaline phosphatase), patient may be included.
- AST, ALT < 2.5 x upper limit of normal
- Albumin > 2.5 g/dl
· Adequate renal function, with serum creatinine < 1.5 x ULN

In Cohort B
· Signed informed consent
· Histologically confirmed adenocarcinoma of the prostate
· Radiographically documented metastatic disease
· Surgical or chemical castration
· PSA > 5 ng/ml
· Androgen-independent disease, as defined by detectable, rising PSA in two consecutive measurements at least one week apart, with a minimum increment of at least 5 ng/ml above the nadir
· Previous treatment with one docetaxel based chemotherapy regimen
· ECOG/WHO performance status of 0, 1 or 2
· Adequate bone marrow reserve(s):
- Neutrophil count > 1,500/ μl
- Platelet count > 100,000/ μl
- Adequate hepatic function:
- Serum bilirubin < 1.0 x upper limit of normal
- Serum alkaline phosphatase < 1.5 x upper limit of normal
- NOTE:  If serum alkaline phosphatase is elevated, measurement of 5’ nucleotidase (5’NT) or gamma glutamyl transferasa (GGT) or alkaline phosphatase liver fraction should be performed, and if either of these is within normal limits (suggesting bone origin of abnormal alkaline phosphatase), patient may be included
- AST, ALT < 2.5 x upper limit of normal
- Albumin > 2.5 g/dl
· Adequate renal function, with serum creatinine < 1.5 x ULN.



E.4 Principal exclusion criteria: In Cohort A:
. Small cell carcinoma of the prostate
· Current treatment with chemotherapy or radiation therapy
· Treatment with extensive external beam radiation therapy or radionuclide therapy within six weeks of study entry. Palliative radiation involving less than 20% of bone marrow reserves must have been completed within four weeks of entry
· Treatment with chemotherapy within 4 weeks of study entry
· Patient not employing adequate contraception
· Other serious illness or medical conditions, specifically:
-  Uncontrolled congestive heart failure or HISTORY of myocardial infection or active
angina pectoris within 6 months preceding registrations
-  Active infectious process
-  Chronic active liver disease, including chronic hepatitis B, chronic hepatitis C, or
cirrhosis
· Current anticancer treatment with any other non-FDA-approved investigational drug
· ECOG performance status of 3 or worse

In Cohort B:
· Small cell carcinoma of the prostate
· Treatment with chemotherapy or radiation therapy was terminated at least 4 weeks before study entry
· Treatment with extensive external beam radiation therapy or radionuclide therapy within six weeks of study entry.  Palliative radiation involving less than 20% of bone marrow reserves must have been completed at least four weeks before study entry
· Treatment with chemotherapy terminated at least 4 weeks before study entry
· Patient not employing adequate contraception
· Other serious illness or medical conditions, specifically:
 -Uncontrolled congestive heart failure or HISTORY of myocardial infection or active angina pectoris within 6 months preceding registrations
- Active infectious process
- Chronic active liver disease, including chronic hepatitis B, chronic hepatitis C, or cirrhosis
· Current anticancer treatment with any other non-FDA-approved investigational drug
· ECOG performance status of 3 or worse


E.5 End points
E.5.1 Primary end point(s): PSA response, duration of response, and time to progression
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): Information not present in EudraCT
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): Information not present in EudraCT
E.7.4 Therapeutic use (Phase IV): Information not present in EudraCT
E.8 Design of the trial
E.8.1 Controlled: No
E.8.1.1 Randomised: No
E.8.1.2 Open: Information not present in EudraCT
E.8.1.3 Single blind: Information not present in EudraCT
E.8.1.4 Double blind: Information not present in EudraCT
E.8.1.5 Parallel group: Information not present in EudraCT
E.8.1.6 Cross over: Information not present in EudraCT
E.8.1.7 Other: Information not present in EudraCT
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): No
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.5 The trial involves multiple Member States: Yes
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: Yes
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:
E.8.7 Trial has a data monitoring committee: Information not present in EudraCT
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: Patients will be assessed for the endpoints of survival, serum PSA and toxicity. Based on these assessments, Yondelis® may be administered until progressive disease or until major toxicity occurs. 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 
E.8.9.1 In the Member State concerned days: 
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 2

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: No
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: Information not present in EudraCT
F.3.3.1 Women of childbearing potential not using contraception : No
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 5
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 5
F.4.2.2 In the whole clinical trial: 49

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2006-08-24
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2006-07-17

P. End of Trial
P. End of Trial Status: Completed
P. Date of the global end of the trial: 2008-11-10

